Helen Torley - 08 Jul 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: HALO
Reported as of: 08 Jul 2026
Net transaction value: -$153,391
SEC form: 4
Accepted by SEC: 09 Jul 2026, 17:19:34 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Oehler, Attorney-in-Fact

Key filing fact

Helen Torley filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 09 Jul 2026.

Key facts

This page summarizes Helen Torley's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jul 2026, 17:19.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$153,391.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001528185 Primary reporting owner

Torley Helen

Relationship: PRESIDENT AND CEO, Director
Address: C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO
Signature: /s/ James R. Oehler, Attorney-in-Fact
Signature date: 09 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HALO transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,923
Change %: +0.25%
Price: $12.07^*
Shares after: 769,703
Date: 08 Jul 2026
Ownership: Direct
Footnotes: F1

HALO transaction

Common Stock

Sale

Transaction value: $70,397
Shares: -888
Change %: -0.12%
Price: $79.28
Shares after: 768,815
Date: 08 Jul 2026
Ownership: Direct
Footnotes: F1, F2

HALO transaction

Common Stock

Sale

Transaction value: $82,994
Shares: -1,035
Change %: -0.13%
Price: $80.19
Shares after: 767,780
Date: 08 Jul 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HALO transaction Derivative

Option to Purchase Common Stock

Options Exercise

Transaction value
Shares: -1,923
Change %: -100%
Price: $12.07^*
Shares after: 0
Date: 08 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,923
Exercise price: $12.07
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.

Footnote F2

Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F3

Represents a weighted average sales price per share. The shares were sold at prices ranging from $79.710 to $80.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Footnote F4

Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.